Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Market Closed 02-06 16:00:00 EST

3.57

+0.18

+5.31%

盘后3.64

+0.07+1.96%

19:11 EST

High3.65	Low3.30	Vol1.57M
Open3.36	D1 Closing3.39	Amplitude10.32%
Mkt Cap386.79M	Tradable Cap259.37M	Total Shares108.35M
T/O5.54M	T/O Rate2.17%	Tradable Shares72.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.57,"timestamp":1770411600000,"preClose":3.39,"halted":0,"volume":1572931,"hourTrading":{"tag":"盘后","latestPrice":3.64,"preClose":3.57,"latestTime":"19:11 EST","volume":5589,"amount":19978.111,"timestamp":1770423096669,"change":0.07,"changeRate":0.019608,"amplitude":0.019608},"delay":0,"changeRate":0.05309734513274328,"floatShares":72651442,"shares":108345239,"eps":-1.3076717,"marketStatus":"Market Closed","change":0.18,"latestTime":"02-06 16:00:00 EST","open":3.36,"high":3.65,"low":3.3,"amount":5541927.9258167995,"amplitude":0.103245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.3076717,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":3.39,"preHourTrading":{"tag":"盘前","latestPrice":3.31,"preClose":3.39,"latestTime":"08:47 EST","volume":13,"amount":45.11,"timestamp":1770385669786,"change":-0.08,"changeRate":-0.023599,"amplitude":0.058997},"postHourTrading":{"tag":"盘后","latestPrice":3.64,"preClose":3.57,"latestTime":"19:11 EST","volume":5589,"amount":19978.111,"timestamp":1770423096669,"change":0.07,"changeRate":0.019608,"amplitude":0.019608},"volumeRatio":1.4185511485719473,"impliedVol":1.4786,"impliedVolPercentile":0.6255},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2608366839","title":"Aclaris Therapeutics to Present at Major Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2608366839","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608366839?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206452,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. will participate in two healthcare conferences in February 2026. On February 12, 2026, Chief Executive Officer Dr. Neal Walker and senior leaders will join a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York. On February 26, 2026, President and COO Hugh Davis, Ph.D., will deliver a corporate presentation at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference. Live and archived webcasts of both events will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the informa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLZ3Sy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","ACRS","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007","LU0314104364.USD"],"gpt_icon":0},{"id":"2608369077","title":"Aclaris Therapeutics to Participate in Two February Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369077","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608369077?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:00","pubTimestamp":1770206400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231905/37216/en/Aclaris-Therapeutics-to-Participate-in-Two-February-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","ACRS","LABU","XLV","BK4588","LU0029874061.USD","HCSG","LU0128526141.USD","BK4581","XBI","BK4585","BK4007"],"gpt_icon":0},{"id":"2606466714","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2606466714","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606466714?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:51","pubTimestamp":1769608260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 08:51 ET (13:51 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2606734134","title":"Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734134","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606734134?lang=en_us&edition=fundamental","pubTime":"2026-01-28 02:12","pubTimestamp":1769537520,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/27/Balding-Man-Showing-His-Head-With-Thin-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/27/Balding-Man-Showing-His-Head-With-Thin-H.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/50167819/aclaris-hair-loss-drug-shows-faster-results-than-pfizers-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/01/50167819/aclaris-hair-loss-drug-shows-faster-results-than-pfizers-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0225284248.USD","SG9999002224.SGD","SG9999001176.USD","LU0225771236.USD","LU0058720904.USD","LU1894683264.USD","IE00BLSP4452.SGD","LU1023059063.AUD","LU0306807586.USD","LU0985481810.HKD","BK4599","BK4550","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU1894683348.USD","BK4153","LU1883839398.USD","LU1057294990.SGD","LU0289739699.SGD","ACRS","BK4568","LU0122379950.USD","IE00B19Z3581.USD","LU0234572021.USD","SG9999002232.USD","BK4592","BK4588","BK4007","BK4533","LU0868494617.USD","BK4581","LU0170899867.USD","SG9999001176.SGD","SG9999003800.SGD","LU1066051498.USD","LU0321505868.SGD","IE00BBT3K403.USD","BK4534","SG9999013999.USD","IE0002270589.USD","LU0321505439.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","SG9999011175.SGD","BK4585","LU0456855351.SGD","BK4217","LU0306806265.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2606893577","title":"Aclaris Therapeutics reports ‘positive’ results from ATI-2138","url":"https://stock-news.laohu8.com/highlight/detail?id=2606893577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606893577?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:01","pubTimestamp":1769515300,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) announced recent positive preclinical results from its potent and selective ITK/JAK3 inhibitor ATI-2138 in a murine mod...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-positive-results-from-ati-2138-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-reports-positive-results-from-ati-2138-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z4B17.USD","LU2065731478.USD","BK4007","IE0031619046.USD","IE00B7SZL793.SGD","ATI","ACRS","IE00B66KJ199.SGD","BK4006","LU1878469433.USD","BK4187"],"gpt_icon":0},{"id":"2606173786","title":"Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606173786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606173786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:55","pubTimestamp":1769514910,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nFWN3YS0MQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2606067786","title":"Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606067786","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606067786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 19:55","pubTimestamp":1769514900,"startTime":"0","endTime":"0","summary":"- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan.  27, 2026  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226283/37216/en/Aclaris-Therapeutics-Novel-ITK-JAK3-Inhibitor-ATI-2138-Demonstrates-Rapid-and-Sustained-Hair-Regrowth-in-Validated-Murine-Model-of-Alopecia-Areata-AA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4187","ATI","ACRS","AA","BK4588","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU1878469433.USD","LU2065731478.USD","BK4153","BK4006","IE00B7SZL793.SGD","BK4007","IE0031619046.USD"],"gpt_icon":0},{"id":"2606223598","title":"Aclaris Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since January 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2606223598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606223598?lang=en_us&edition=fundamental","pubTime":"2026-01-27 03:29","pubTimestamp":1769455740,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics, Inc.  is currently at $3.82, down $0.68 or 15.11%. --Would be lowest close since Jan. 16, 2026, when it closed at $2.62. --On pace for largest percent decrease since Jan. 10, 2024, when it fell 21.48%. --Currently down two consecutive days; down 15.67% over this period. --Up 26.91% month-to-date; on pace for best month since Oct. 2025, when it rose 32.63%. --Down 88.42% from its all-time closing high of $32.99 on April 17, 2017. --Up 55.92% from 52 weeks ago , when it closed at $2.45. --Up 253.7% from its 52-week closing low of $1.08 on April 10, 2025. --Down 16.22% at today's intraday low; largest intraday percent decrease since Nov. 20, 2024, when it fell as much as 20.04%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2605636109","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2605636109","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605636109?lang=en_us&edition=fundamental","pubTime":"2026-01-21 19:38","pubTimestamp":1768995480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 21, 2026 06:38 ET (11:38 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2605117503","title":"Aclaris Therapeutics Up Over 32%, On Track for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605117503?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:08","pubTimestamp":1768925280,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics, Inc.  is currently at $3.47, up $0.85 or 32.45%. --Would be highest close since Dec. 11, 2024, when it closed at $3.54. --On pace for largest percent increase since Nov. 19, 2024, when it rose 46.18%. --Down 89.48% from its all-time closing high of $32.99 on April 17, 2017. --Up 33.47% from 52 weeks ago , when it closed at $2.60. --Traded as high as $3.57; highest intraday level since Dec. 12, 2024, when it hit $3.57. --Up 36.26% at today's intraday high; largest intraday percent increase since Nov. 19, 2024, when it rose as much as 64.65%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2602511043","title":"Aclaris Therapeutics Launches Phase 1b Trial of Bispecific Antibody ATI-052 in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511043","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511043?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218929,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. has announced the initiation of a placebo-controlled Phase 1b proof-of-concept trial for ATI-052, its investigational bispecific anti-TSLP/IL-4Rα antibody, in patients with moderate-to-severe atopic dermatitis. The trial will assess the safety, tolerability, and clinical efficacy of ATI-052, as well as pharmacokinetic and pharmacodynamic endpoints. Additionally, Aclaris plans to begin a Phase 1b proof-of-concept trial for ATI-052 in asthma within the first quarter of 2026. Top line results from both trials are expected to be presented in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNews","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL338vJb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","NDAQ","ACRS","BK4007","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2602511095","title":"Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Atopic Dermatitis (Ad) With Its Novel Bispecific Antibody ATI-052","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511095?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2602511091","title":"Aclaris Therapeutics Inc - Top Line Results From Poc Trials Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602511091?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2602110995","title":"Aclaris Therapeutics Inc - to Initiate Phase 1B Trial in Asthma This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2602110995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602110995?lang=en_us&edition=fundamental","pubTime":"2026-01-12 19:55","pubTimestamp":1768218900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7CSW1B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2601817333","title":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla","url":"https://stock-news.laohu8.com/highlight/detail?id=2601817333","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601817333?lang=en_us&edition=fundamental","pubTime":"2026-01-07 02:50","pubTimestamp":1767725435,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, TeslaEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FGBI","PNC","NEM","ACN","ANGO","ALB","ACRS","PUMP","EPAM","STAA","VRTX","WMB","APGE","BAC","CFG","OS","SG","REGN","VST","EXE","CNX","LUV","COP","UAL","TPG","AIG","BALL","LYFT","TFC","AEVA","EAT","NTRS","UAA","IMSR","JXN","EQIX","CRNX","NBP","FIX","IFF"],"gpt_icon":1},{"id":"2601819813","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin","url":"https://stock-news.laohu8.com/highlight/detail?id=2601819813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601819813?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:52","pubTimestamp":1767714720,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed MartinEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQIX","GILD","DLR","OS","LMT","VRTX","VST","BALL","STT","HL","UAA","ALB","CORZ","NTRS","NBP","GNPX","CFG","MCHP","IFF","CDE","ANGO","BK","FERG","EPAM","AIG","ZETA","ALKS","ACN","JXN","BAC","GL","CRNX","INTU","TFC","PNC","REGN","ACRS","ALMS","STAA","NEM","O","SHAK","AEVA","APGE","IMSR"],"gpt_icon":1},{"id":"2601180648","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2601180648","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601180648?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:12","pubTimestamp":1767708743,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridgeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL6N3Y70M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDU","OS","ALKS","AU","ALB","CDE","HL","ACN","ANGO","ZETA","ACRS","NTRS","NVD3.UK","BALL","AIG","GILD","BK","AEVA","VERX","NVDX","RTO.UK","NVDS.UK","STT","HGT.UK","NVIW.SI","NVDS","NEM","NVD2.UK","JXN","MCHP","INTU","REGN","VRTX","GL","IFF","NBP","APGE","GNPX","FERG","O","NVDY","VST","UAA","CRNX","ALMS"],"gpt_icon":1},{"id":"2601937897","title":"Aclaris Therapeutics Says Phase 1 Trial of Dermatitis Therapy Candidate ATI-052 Shows 'Strong Safety' Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2601937897","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601937897?lang=en_us&edition=fundamental","pubTime":"2026-01-06 21:02","pubTimestamp":1767704534,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics  said Tuesday its atopic dermatitis and asthma therapy candidate ATI-052 showed a 'strong safety and tolerability profile' in interim phase 1 trial results.The interim data also showed the candidate had a 'dose proportional pharmokinetic profile, and concentration-dependent pharmacodynamics even at the lowest dose.'Aclaris plans to initiate phase 1b trials for atopic dermatitis 'imminently' and asthma therapy in Q1, with top line data from both trials to be released in H2.The company is also planning a phase 2b trial of ATI-052 in atopic dermatitis to begin in H2.Shares of the company were up 3.4% in recent Tuesday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065731478.USD","IE00B19Z4B17.USD","ACRS","ATI","BK4006","IE00B7SZL793.SGD","IE0031619046.USD","IE00B66KJ199.SGD","LU1878469433.USD","BK4007","BK4187"],"gpt_icon":0},{"id":"2601544892","title":"BUZZ-Aclaris rises as inflammation drug shows promise in early trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601544892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601544892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:31","pubTimestamp":1767702689,"startTime":"0","endTime":"0","summary":"BUZZ-Aclaris rises as inflammation drug shows promise in early trial** Shares of drug developer Aclaris Therapeutics ACRS.O rise 2.3% to $2.71 premarket** Co says its experimental drug ATI-052 showed promising safety and effectiveness in an early-stage clinical trial** ATI-052 aims to treat atopic dermatitis, or eczema, and asthma by blocking inflammation signals - ACRS** Co says drug was well tolerated, with mild side effects such as temporary redness at injection site** ATI-052 stayed in body for 26 days, and may allow dosing once every three months - ACRS** Co plans proof-of-concept trials early this year; larger mid-stage trial in second half of 2026** As of last close, ACRS up ~44% over the past year","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL4N3Y70RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2601917888","title":"Aclaris Therapeutics Inc: Expects Top Line Data From Both Trials in Second Half of 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601917888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601917888?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:59","pubTimestamp":1767700740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nTUA2QKXZK:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ACRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":0.3321},{"period":"3month","weight":0.5388},{"period":"6month","weight":1.1902},{"period":"1year","weight":0.4691},{"period":"ytd","weight":0.186}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.145543},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.020588},{"month":3,"riseRate":0.4,"avgChangeRate":-0.054834},{"month":4,"riseRate":0.4,"avgChangeRate":-0.010072},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.092435}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}